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Cancer is a global burden that has prompted extensive research into prevention and treatment, over many decades. Scientific
studies have shown that subset of cells within a tumour, known as cancer stem cells (CSCs), are responsible for tumourigenesis,
metastasis, drug resistance, and recurrences. CSCs have characteristic features of enhanced self-renewal, proliferation, and limited
but multidirectional differentiation capacity. The discovery of CSCs has initiated extensive research into novel cancer treatment
regimes. Evidence indicates that CSCs are resistant to conventional chemo- and radiation therapy leading to treatment failures,
cancermetastasis, secondary cancer formation, and relapse. Because of the observed phenomena in the course of cancer prognosis,
a need for treatment modalities targeting CSCs is important. Photodynamic therapy (PDT) is a clinically approved, minimally
invasive, therapeutic procedure that can exert a selective cytotoxic activity toward cancerous cells while reducing toxicity to normal
cells. It uses a photosensitizer (PS) that becomes excited when subjected to light at a specific wavelength, and the PS forms reactive
oxygen species (ROS) killing malignant cells. Currently, PDT is being investigated as a target specific treatment for CSCs by the
addition of carrier molecules and antibody conjugates bound to the PS. Targeted PDT (TPDT) may be able to not only eradicate
the tumour mass but kill CSCs as well.
1. Introduction
Cancer is a global burden, affecting people from all socioe-
conomic backgrounds, in all geographic regions of the world.
This disease is responsible for 1 in 7 deaths worldwide and is
predicted to affect 21.6 million people and 13 million deaths
by the year 2030 [1]. To effectively combat cancer in modern
medicine, much attention is being directed toward cancer
prevention and treatment, while concurrently investigating
causes of cancer and cancer dynamics [2]. Cancer is caused
by a genetic mutation, on a cellular level, where errors in
DNA instructions lead to cells evading normal cell cycle
functions specifically cell cycle arrest [3]. Along with cancer
cells evading cell cycle arrest cancer can have the ability to
metastasize and recur even after conventional therapy. Recent
evidence has shown that a subset of cells called cancer stem
cells (CSCs) can initiate tumour formation [4]. This small
subpopulation of cells resides within the tissue mass and has
characteristics that include self-renewal, differentiation, and
tumourigenicity when transplanted into an animal host. A
number of cell surface markers such as CD44, CD24, and
CD133 are oftenused to identify and enrichCSCs.The clinical
relevance of CSCs has been strengthened by emerging evi-
dence demonstrating that CSCs are resistant to conventional
chemotherapy and radiation treatment and that CSCs are
very likely to be the origin of cancer metastasis. CSCs are
believed to be an important target for novel anticancer drug
discovery [5].
Photodynamic therapy (PDT) is a well-documented ther-
apy that has emerged as an effective treatment modality
of cancer [6]. It involves the use of a nontoxic dye, or
photosensitizer (PS), which is effectively activated by light at
a specific wavelength [7]. This then generates singlet oxygen,
or other reactive oxygen species (ROS), causing degradation
of cellular components by damaging different biomolecules
including proteins, DNA, and lipids leading to cancer cell
destruction and death [8, 9]. According to Abrahamse et al.
(2016) optimum standards of a good PS include being a single
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pure compound, having a strong absorption peak in the red
to near infrared spectral region (between 650 and 800 nm),
possessing a substantial triplet quantum yield, and having no
dark toxicity and a relatively rapid clearance rate fromnormal
tissues [6]. Along with a PS having optimum standards,
what distinguishes PDT from conventional therapies such as
chemotherapy is its affinity for malignant cells that results in
selective cytotoxic effects, killing cancer cells with minimal
effects on normal cells, unlike chemotherapy and genotoxic
drugs that destroy the cancer cells and its surrounding
normal tissue [10].
PDT can further be enhanced by making it target defini-
tive. This can be done with the addition of nanoparticles
and monoclonal antibodies to enhance tumour selectivity,
PS absorption, and cell specificity. Nanoparticles (NPs) are
currently being used for tumour imaging in vivo, profiling
of cancer biomarkers, and targeted drug delivery [11]. They
have also been used to increase solubility and improve
the transcytosis of PSs through membranes and endothelial
barriers. The combined use of NPs and monoclonal anti-
bodies concurrently has potential for a very high therapeutic
efficacy. This review will focus on the aspect of the stem cell
theory, CSCs, and the potential role of targeted PDT using
nanoparticles and monoclonal antibodies.
2. Cancer
TheNational Cancer Institute defines cancer as a collection of
diseases in which cells of the body begin to grow uncontrol-
lably and spread to other tissues. Although there are different
theories of how cancer develops and many derangements
involved, they are all attributed to DNA damage that alters
the normal cellular growth pathways. Mutations in genes that
control normal cellular functions result in a dysregulated
growth of cells, followed by uncontrolled replication of cells
that finally outgrow normal cells to form a tumour mass [12].
Biologically, cancer is a genetic disease but not, with a few
exceptions, inheritable. Only a few cases where mutations are
inherited as a single gene disorder can cause cancer.
2.1. Molecular Biology of Cancer. Since the beginning of
the era of oncology, a multitude of research has been
done to understand the molecular mechanisms of cancer.
Hippocrates was among the first scientists to describe the
different forms of tumours and called them “cancer” that
described the crablike shape of the tumour invading normal
tissue. Research is still ongoing in hopes to elucidate on
cancer biology at the molecular level and new discoveries are
documented on regularly [13].
A deep understanding of the molecular mechanisms of
cancer is, however, essential for the development of novel
therapeutic modalities. As described previously, cancer is
a result of dysregulated cell growth. In a normal cell, all
cellular processes from cell birth, growth, proliferation, divi-
sion, and death respond to stimulatory or inhibitory signals
transmitted from regulatory genes and signalling molecules,
both intracellularly and extracellularly [13, 14]. Thus, the cell
cycle is an extensively regulated process. In addition to the
key proteins in cell cycle regulation, Cyclins, and Cyclin
Table 1: Characteristics of cancer cells.




Lack of Contact inhibition
Formation of blood vessel network
Invasiveness
Metastasis
Dependent Kinases, there are genes that normally stimulate
cell growth called proto-oncogenes which when mutated
becomedominant-acting stimulatory genes that cause cancer.
These cancer causing genes are, therefore, termed oncogenes.
A cell also has inhibitory genes that suppress cell growth,
called tumour-suppressor genes, which code for regulatory
proteins, the most common of which are p53 and the
Retinoblastoma [14]. When a cell suffers a dysfunction of
these proteins, unregulated growth issues occur. Mutations
in regulatory genes may result in the activation of onco-
genes and downregulation of genes that suppress tumour
formation; this alongside other mutations inactivating genes
responsible formaintaining genomic integrity initiates cancer
[15]
.
2.2. Characteristics of Cancer Cells. Biologically, cells in the
same tumour differ in virtually all phenotypic features.
Cancer cells, at different levels of development arising
from the same clone of cells, have variations in morphol-
ogy, gene expression, metabolism, motility, proliferative,
immunogenic, and metastatic potential. Cancer begins at a
cellular level in a multistep process involving the activation
of cells that produce cancer cells commonly referred to as
Cancer Stem Cells (CSCs) [16, 17]. These cells lose their
cellular features of terminal differentiation (dedifferentiation)
and increase in fraction of tissue outgrowing normal cells
alongside faulty tissue repair. Finally, for a cancer cell to
proliferate it overrides the process of replicative senescence
to become immortal and obtains a supply of nutrients and
oxygen that maintains the high rate of proliferation. This
phenomenon is achieved by the cells ability to secrete a
protein, called vascular endothelial growth factor in response
to hypoxia. A cancer cell also secretes its own hormones and
signal transduction molecules [14]. The molecules that are
not expressed in normal cells are a characteristic feature that
makes it possible to target cancer cells for drug delivery.These
and other characteristics of cancer cells are summarised in
Table 1.
3. Cancer Stem Cells
3.1. The CSC Hypothesis. The cancer stem cell hypothesis is
grounded by the following conditions: a tumour is defined,
on a cellular level, by uncontrolled proliferation caused by
the addition of random mutations in critical genes that
control cell growth. Although gene mutations cause cancer,
it has been reported that malignancy can be caused by a
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Table 2: Specific CSC markers and function [adapted from [25]].
CSC Marker Function
Glioma CD 49f Cell adhesion
Ovary CD 117 SC-factor receptor
Liver CD 13 Kidney disease marker
Lung CD 56 Cell adhesion
Renal CD105 Co-receptor TGF-𝛽
Neuroblastoma CD 114 Colony stimulating factor 3 receptor
Gastric CD 54 Cell adhesion
Leukaemia TIM-3 Immune checkpoint receptor
CD 96 T-cell specific receptor
CD 9 Cell adhesion
Breast CD 55 Complement inhibitor
Melanoma CD 20 B-cell lineage
ABCB 5 ABC transporter
subpopulation (SP) of cells found within the tumour, called
CSCs, thought to be responsible for tumorigenesis, tumour
maintenance, tumour spread, and tumour relapse [18]. Adult
stem cells (ASCs) are responsible for tissue renewal and
repair. Stem cell characteristics include their ability for self-
renewal without loss of proliferation capacity; they are per-
durable and drug resistant and capable of differentiating into
any type of adult cell in the body due to the influence of micro
environmental and some other factors. Asymmetric division
allows for stem cell (SC) survival giving one daughter cell
the ability for self-renewal and the other differentiation and
proliferation capacity. Cancer stem cells share characteristics
similar to normal SCs and express SC representing markers
[19].These CSCsmake up as few as 1% of the cells in a tumour,
making them difficult to detect and study. Like normal SCs,
CSCs have a number of properties permitting them to sur-
vive traditional cancer chemotherapy and radiation therapy.
These cells express high levels of ATP-binding cassette drug
transporters, providing for a level of resistance, are relatively
quiescent, and have higher levels ofDNArepair and a lowered
ability to enter apoptosis [20].ThemechanismbywhichCSCs
originate is (either) by normal SCs that underwent genetic
and epigenetic changes and (or) by dedifferentiation from
somatic tumour cells [19].
3.2. CSC Identification and Enrichment. The first evidence
of CSCs was seen in a study conducted on acute myeloid
leukaemia in 1994. This SP of cells was transplanted into
immunocompromised mice. The cells were enriched using
surface markers (CD34+/CD38−) and were identified as
tumour initiating [21]. Cancer stem cells have been identified
in solid tumours, including breast, brain, colon, pancreas,
lung, prostate, melanoma, and glioblastoma, all capable of
inducing malignancy in nonobese diabetic/severe combined
immune deficient (NOD/SCID) mice [22, 23]. A variety of
cell surface markers have been used to isolate and enrich
CSCs.The expressions of CSC surface markers are tissue type
and tumour type-specific. Enhanced identification and tar-
geting of CSCs involve the use of multiple and a combination
of surface markers [24]. Kim et al. (2017) conducted a study
where 40 CSC surface markers were classified into 3 different
categories, depending on their expression on human embry-
onic SCs, ASCs, and normal tissue cells. More than 80% of
the markers were shown not to be expressed on normal tissue
cells, making the CSC surface markers useful therapeutic
targets against CSCs due to their low cross-reactivity to
normal tissue cells [25]. The similarity between normal SC
and CSC surface markers suggests that CSCs predominantly
originate fromnormal SCs via the accumulation of epigenetic
and genetic alterations [26]. Table 2 highlights some of the
CSCmarkers, and themarkers are specific to the type of CSC,
as well as their function.
3.3. CSCs and Conventional Cancer Therapy. The role CSCs
play in cancer relapse and metastasis is seen in their ability to
be chemo- and/or radiation-therapy resistant (Figure 1). This
has beenproven by different researchers, whereby the propor-
tion of cell SPs was examined before and after chemotherapy.
The SP consisting of CSCs had a significant increase in their
mean value after treatment [5]. However, controversial results
have also been reported, where two patients being treated
for CSC therapy resistance were assessed. The radiation
resistance of breast CSCs was tested using early passage,
patient-derived xenografts from two separate patients. The
CD44+CD24−/low Lineage− and ALDH+ breast CSCs from
one patient showed depletion of the SP of cells after radiation
therapy as well as decreased tumour sphere frequency and
tumorigenic capacity. In contrast, CSCs from the other
patient displayed enrichment after irradiation and resistance
to therapy [27].
4. Photodynamic Therapy
Photodynamic therapy is a well-studied therapy for cancer. It
uses PSs (nontoxic dyes) that are activated by absorption of
visible light to initially form the excited singlet state, followed
by transition to the long-lived excited triplet state.This triplet
state can undergo photochemical reactions, in the presence
of oxygen, to form ROS (including singlet oxygen) that can
destroy cancer cells [6]. The therapeutic effect of PSs lies in
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Figure 1: CSCs and conventional cancer therapy. Chemo- and radiation therapy fail to eradicate CSCs, which can lead to cancer relapse and
metastasis.
their binding capacity, as they preferentially bind to intracel-
lular organelles causing photo-oxidative damage to proteins
and lipids that reside within a few nanometres of the PS bind-
ing sites [28]. Selective cell destruction of PDT is achieved
through its enhanced permeability retention (EPR), seen
in malignant cells, minimizing destruction of noncancerous
tissue [29].Other theories document localization to increased
expression of certain receptors on tumour cells, decreased
intratumoural pH, or tumour-associated macrophages that
phagocytise PS molecules [30]. Depending on the structural
characteristics of the PS it will be localized in different
organelles. It has been shown that overall charge, charge dis-
tribution, lipophilicity, and overall structure predominantly
determine cellular uptake and subcellular localization of a PS
and ultimately determine its therapeutic effect [31].
4.1. PDT and Cancer. Photodynamic therapy proves to be
operative as an anticancer treatment as well as improving
patient survival. Efficacy is seen when PDT is part of a
multimodal approach and is used as the first-line treatment
for premalignant or early disease and as stand-alone palliative
treatment. Even though PDT shows great potential, there are
still some limitations that prevent a firm position for PDT in
the standard care regimen of cancer [21]. A drawback com-
monly seen is decreased efficacy of PDT for larger lesions, due
to inadequate tissue penetration of light or PS [32]. Besides
larger lesions, PDT is also not indicated for metastasizing
tumours. Metastasis remains one of the largest challenges in
cancer therapy and PDT is no exception. Tumour recurrence
is often reported where inadequate tumour eradication is
noted. This is said to be due to insufficient penetration,
but also the presence of PDT resistant tumour tissues [33].
The limitations of PDT mentioned above can be ascribed
to CSCs having characteristics significant to PDT evasion,
such as metastasis and drug evasion through their multidrug
efflux pumps. This has been proven in a study conducted by
Morgan et al. (2010), where a SP of cells containing the ATP-
dependent transporter ABCG2 gene, a multidrug resistant
pump, was responsible for initiating tumour regrowth after
PDT treatment. The ABCG2 may lower intracellular levels of
substrate PS below the threshold for cell death in tumours
treated by PDT, leaving resistant cells to repopulate the
tumour [34]. Hence the need to revolutionise PDTbymaking
it more target specific.
4.2. Targeted PhotodynamicTherapy Using Immunoconjugates
andCarrierMolecules. In cell biology, the nucleus is shown to
be the most hypersensitive intracellular organelle and hence
therapies targeting the nucleus tend to be more effective than
those that are limited to the cytoplasm [35]. To achieve a tar-
geted drug delivery system, suitably engineered biomolecules
have been the field of focus for oncology researchers. A cell
targeting biomolecule can be synthesized by combining two
or more particles each having specific functions to target
biological components of living systems, including antigens
and molecules inside, or on the surface of cells.
Studies have been focused on developing antibody-
directed phototherapy (ADP), where antibody conjugation
is used to deliver PSs to the tumour via tumour-associated
surface markers. Targeting improves both specificity and
efficiency and overcomes some of the current limitations of
nontargeted PDT. The PS, when passing into the tumour
microenvironment, can diffuse into cells or reside in the
extracellular/cell surface environment depending on their
physical properties. This in turn may also depend on the
antibody. Photosensitizers that are hydrophobic in nature
may be able to cross cellular membranes directly along their
concentration gradient, and PS-drugs that have associated
with lipid binding proteins such as low-density lipoprotein
or human serum albumin can get taken up, specifically
via cell surface receptors. Antibody-directed phototherapy
refines this receptor delivery by using antibodies (Abs) to
deliver PS-drugs to cell surface markers overexpressed on
tumour cells; these can then specifically induce ADP-drug
internalisation [36]. This theory was proven by Vrouenraets
et al., where the PS aluminium (III) phthalocyanine tetra-
sulfonate [AlPc(SO3H)4] a hydrophilic compound was used.
This PS in its free form does not reach the critical intracellular
target, making it ineffective. A monoclonal antibody was
conjugated to the PS and had shown preservation of integrity
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and immunoreactivity and full stability [37]. Internalisa-
tion of this ADP-drug showed increased cytotoxicity and
selective tumour targeting making it an ideal approach to
enhance PDT. Another form of ADP is Near Infrared-
Photoimmunotherapy (NIR-PIT), which is cancer therapy
utilizing an antibody-photoabsorber conjugate (APC) and
specifically near infrared light (NIR-light) to activate the PS.
The significance of using a PS that is activated by NIR is
the properties of the light being harmless to surrounding
normal tissue and its penetration depth of 1-2 cm, making
it specifically useful on surface tumours [38]. This treatment
also exploits the overexpression of specific antigens on a
variety of cancer cells, such as mesothelin. The Ab directed
against mesothelin (hYP218) shows a high binding affinity
between the Ab and antigen pair, supporting highly selective
cell killing when applied as an ADP. A study that demon-
strated the use of NIR-PIT was conducted by Nagaya et al.
(2016), where they used aPS (IR700) conjugated to hYP218 on
an epidermoid carcinoma cell line. The results showed high
tumour accumulation and a high tumour-background ratio
as well as a significant decrease in cancer cell survival when
compared to their controls [39]. Another study that evaluated
the use of NIR-PIT in vivo was conducted by Mitsunaga
et al. (2011), where they conjugated IR700 to epidermal
growth factor (EGF) receptors. This form of molecular-
targeted cancer therapy showed tumour shrinkage, where
cells expressing the EGF showed membrane damage leading
to tumour cell death [40]. The results obtained from the
studies indicate that ADP whether it be internal or external
targeting using an Ab directed at specific antigens expressed
by cancer cells can successfully be implemented as a method
for advancing PDT.
Along with ADP, the anticancer response of a PS can fur-
ther be enhanced using a carrier molecule. Carrier molecules
in the form of nanoparticles (NPs) can accumulate in a
tumour because of the well-known enhanced permeability
retention (EPR) effect. These molecules can be adapted
specifically to their application by changing its composition
that will enable receptor targeting through overexpression of
surface markers on the malignant cells, and they can enhance
photon absorption and improve singlet oxygen by the surface
plasmon resonance effect specifically gold nanoparticles [41],
which can lead to increased ROS and cancer cell destruction.
Biodegradable and nonbiodegradable NPs can be used in this
application. Biodegradable NPs degrade in their biological
environment through a hydrolytic process, releasing the PS.
Using a NP that is internalised by the cell has an
advantage over external NPs loaded with PSs. It can be said
that the photoactivity of a PS loaded NP depends on its
photochemical and cell penetrating properties; furthermore
the NP activity in vivo is governed by pharmacokinetics and
tissue distribution. Extravasation of the NP is dependent
on its size, also affecting photodynamic activity. A smaller
NP has greater photodynamic effect and clears out faster
from the bloodstream. Nonbiodegradable NPs have the
advantage of actively delivering singlet oxygen. This can be
achieved externally through membrane contact, as well as
internalisation through its cell penetrating properties giving
photosensitivity to the targeted tumour tissue. They have
enhanced particle residence time allowing for the photo
action to be monitored over time. Nonbiodegradable NPs
also have the following advantages over biodegradable NPs:
they are stable in fluctuating pH and temperature and they are
easily manipulated to specificities during development, evad-
ing bacterial contamination and they allow for PS retention
and singlet oxygen diffusion due to its pore size [41].
Figure 2 graphically represents the advantages of using
multicomponent photosensitizing molecules and their differ-
ent roles in TPDT.
In a study by Stuchinskaya et al., a 4-component photo-
sensitizing compound composed of phthalocyanine PS, an
antibody (anti-HER2 monoclonal Ab), polyethylene glycol
and an Au-NP, was used as a potential drug for targeted
photodynamic cancer therapy. This multicomponent drug
proved to be more stable toward aggregation and efficiently
produced cytotoxic singlet oxygen under irradiation with
visible red light. This study showed that the coupling of PSs,
NPs, and antibodies in one biomolecule selectively targeted
breast cancer cells that showed overexpression of HER2 EGF
cell surface receptor [42].
A study conducted on mice for central- and peripheral-
type early-stage lung cancer using tissue factor to improve
the selectivity and effectiveness of nontargeted PDT (ntPDT)
showed that factor VII-targeted PDT (fVII-TPDT) using
fVII-Sn(IV) chlorin e6 Dihydroxide Trisodium Salt signifi-
cantly enhanced (up to 25-fold) the in vitro effect, destroying
A549 and H460 lung cancer cells via the rapid induction of
apoptosis and necrosis. In vivo administration of fVII-TPDT
significantly inhibited or eliminated subcutaneous A549 and
H460 tumour xenografts in an athymic nude mouse model
without any obvious side effects [43].
Work conducted by Yu et al. [44] using an effective
PS, methylene blue (MB), combined with Au-NPs, was
prepared using an intermolecular interaction between a
polystyrene-alt-maleic acid layer on the Au-NPs and MB.
TheAu@polymer/MBNPs produced a high quantum yield of
singlet oxygen molecules, 50%more that that of freeMB, and
they were then excited by laser with a wavelengths of 660 nm,
having little to no dark toxicity. Furthermore, transferrin was
conjugated on the Au@polymer/MB NPs via an EDC/NHS
reaction to enhance the selectivity to HeLa cells compared
to 3T3 fibroblasts. With a hand-held single laser treatment
(32 mW/cm) for 4 min, the new Au@polymer/MB-Tf NPs
showed a 2-fold enhancement of PDTefficiency towardHeLa
cells over the use of free MB at 4 times dosage. Biological
experiments showed that the HeLa cells reacted well with
Au@polymer/MB-Tf NPs and PDT was achieved leading to
apoptosis.
One of the first nanoplatforms to be applied in drug
delivery systems are liposomes. Their ability lies within their
containment of hydrophilic drugs in their aqueous core
and hydrophobic agents within their lipid bilayers, mak-
ing them efficient delivery vehicles. 5-Aminolevulinic acid
(ALA) prodrugs for PDT were encapsulated in dipalmitoyl-
phosphatidyl choline–based liposomes. In vitro experi-
ments demonstrated an increased uptake of the conjugated
molecule into human cholangiocarcinoma HuCC-T1 cells
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Figure 2: Advantages of using multicomponent photosensitizing molecules and their different roles in TPDT: (1) Conjugating a PS to NPs
and antibodies increases its stability in the circulation and tumour selectivity. (2) Antibodies recognise specific antigens on the surface of
cells enabling specific binding. (3) Nanoparticles enhance endothelial membrane by increasing solubility. (4) Because of increased solubility,
there is maximum absorption resulting in efficient accumulation of photosensitizer inside the cancer cell. (5) Ultimately, there is increased
cytotoxic effect in PDT.
compared to ALA alone having an increased photocy-
totoxic effect [45]. Magnetoliposomes (MLs) loaded with
zinc phthalocyanine (ZnPc)/cucurbituril (CB) complexes
(CB:ZnPc-MLs) were synthesized for TPDT and magne-
tohyperthermia in malignant melanoma cells. Significant
reduction in cell viability was observed with melanoma cells
treated with CB: ZnPc-MLs after application of both 670
nm light and AC magnetic field. The combined PDT and
magnetohyperthermia by CB:ZnPcMLs were much more
effective than each therapy alone [46].
In a study conducted by Governatore et al., they explored
the use of ADP constructed from mAbs targeted against
colorectal cancer antigens, to increase the selectivity of the PS
for tumour over normal tissue. The PS chlorine6 (ce6) was
conjugated to anticolon cancer monoclonal antibody 17.1A.
Polylysine linkers bearing several ce6 molecules were cova-
lently attached in a site-specific manner to partially reduced
IgG molecules, which allowed photoimmunoconjugates to
bear either cationic or anionic charges. The conjugates
retained immunoreactivity. The cationic photoimmunocon-
jugate delivered 4 times more ce6 to the cells than the
anionic photoimmunoconjugate, and both 17.1A conjugates
showed, in comparison to nonspecific rabbit IgG conjugates,
selectivity for antigen positive target cells. Illumination with
only 3 J cm2 of 666 nm light reduced the cell viability
over 90% for the cationic 17.1A conjugate and by 73% for
the anionic 17.1A conjugate after incubation with 1 𝜇M ce6
equivalent of the respective conjugates. By contrast, 1 𝜇M free
ce6 gave only a 35% reduction in viability [47].
The results of this study strongly suggest the significance
of using NPs and antibodies in TPDT.
Table 3 is a representation of where targeted therapy
through conjugation of NPs or antibodies has advanced
conventional cancer therapies.
This technology can be applied to CSCs as well, allowing
for not only the cytotoxicity of the tumour but the SP of cells
(CSCs) residing within it, sparing side effects in surrounding
normal tissues. A representation of the above mentioned
therapy is illustrated in Figure 3.
5. Conclusion
Conclusive evidence indicates that CSCs play the major roles
in therapeutic resistance due to their significant character-
istics of self-renewal, drug resistance, differentiation, and
metastasis. Other studies also suggest that the proportion
of CSCs within a tumour may correlate with the severity
of the cancer. Because CSCs are able to evade the effects of
conventional therapies there is, therefore, a need for targeted
therapies with the purpose of enhancing patient survival by
minimizing cancer recurrence, side effects, and metastasis.
Scientific evidence suggests that improved cancer treatment
and targeted therapies are expected to yield the highest
cure rates. However, current methods are limited by their
low sensitivity to early disease and a lack of specificity for
targeted cell killing, as well as therapy resistance due to
CSCs. PDT using targeted drug delivery systems comprised
of PSs coupled to nanoparticles and monoclonal antibodies
has potential to successfully treat cancer. Antibodies can
assist in the accurate detection of tumour cells and provide
increased PS accumulation in CSCs, along with nanoparticles
that can increase EPR and cellular uptake, making TPDT
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Table 3: Cancer and TPDT.
Cancer TPDT Reference
Breast Cancer Phthalocyanine conjugated to anti-HER2 monoclonalAb, polyethylene glycol and Au-NP [42]
Lung Cancer Sn(IV) Chlorin e6 Dihydroxide Trisodium Saltconjugated to factor VII [43]
Cervical Cancer Methylene Blue conjugated to Au-NPs and Transferrin [44]
Cholangiocarcinoma
(Bile Duct Cancer)
5-Aminolevulinic acid conjugated to
dipalmitoyl-phosphatidyl choline–based liposomes [45]
Melanoma zinc phthalocyanine (ZnPc)/cucurbituril (CB)conjugated to Magnetoliposomes [46]
Colon Cancer chlorine6 (ce6) conjugated to anti-colon cancermonoclonal antibody 17.1A [47]
Tumour mass consisting of 
cancer and CSCs
Targeted PDT consisting of 
a PS + NP + Ab
Eradication of the tumour 
mass, as well as CSCs, 






Figure 3: CSCs and targeted PDT using antibodies and nanoparticles. TPDT targeting cancer as well as CSCs, eradicating the entire tumour
that advocates for normal healthy tissue growth.
a study of interest due to its therapeutic enhancements
including efficacy, specificity, marginal toxicity to normal
cells, biocompatibility, and minimal side effects.
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